PMID- 24836679
OWN - NLM
STAT- MEDLINE
DCOM- 20141110
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1846
IP  - 1
DP  - 2014 Aug
TI  - Angiogenic factors as potential drug target: efficacy and limitations of 
      anti-angiogenic therapy.
PG  - 161-79
LID - S0304-419X(14)00047-X [pii]
LID - 10.1016/j.bbcan.2014.05.002 [doi]
AB  - Formation of new blood vessels (angiogenesis) has been demonstrated to be a basic 
      prerequisite for sustainable growth and proliferation of tumor. Several growth 
      factors, cytokines, small peptides and enzymes support tumor growth either 
      independently or in synergy. Decoding the crucial mechanisms of angiogenesis in 
      physiological and pathological state has remained a subject of intense interest 
      during the past three decades. Currently, the most widely preferred approach for 
      arresting tumor angiogenesis is the blockade of vascular endothelial growth 
      factor (VEGF) pathway; however, the clinical usage of this modality is still 
      limited by several factors such as adverse effects, toxicity, acquired drug 
      resistance, and non-availability of valid biomarkers. Nevertheless, angiogenesis, 
      being a normal physiological process imposes limitations in maneuvering it as 
      therapeutic target for tumor angiogenesis. The present review offers an updated 
      relevant literature describing the role of well-characterized angiogenic factors, 
      such as VEGF, basic fibroblast growth factor (bFGF), platelet derived growth 
      factor (PDGF), placenta growth factor (PLGF), hepatocyte growth factor/scatter 
      factor (HGF/SF) and angiopoetins (ANGs) in regulating tumor angiogenesis. We have 
      also attempted to discuss tumor angiogenesis with a perspective of 'an attractive 
      target with emerging challenges', along with the limitations and present status 
      of anti-angiogenic therapy in the current state-of-the-art.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Gacche, Rajesh N
AU  - Gacche RN
AD  - School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded-431 
      606 (MS), India. Electronic address: rngacche@rediffmail.com.
FAU - Meshram, Rohan J
AU  - Meshram RJ
AD  - School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded-431 
      606 (MS), India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140513
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Angiogenic Proteins)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Angiogenic Proteins/*antagonists & inhibitors
MH  - Animals
MH  - Cell Proliferation/drug effects
MH  - Genes, Switch
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Neoplasms/*blood supply/*drug therapy
MH  - Neovascularization, Pathologic/*drug therapy/genetics
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-angiogenic therapy
OT  - Pro-angiogenic cytokines
OT  - Tumor angiogenesis
EDAT- 2014/05/20 06:00
MHDA- 2014/11/11 06:00
CRDT- 2014/05/20 06:00
PHST- 2014/02/19 00:00 [received]
PHST- 2014/05/05 00:00 [revised]
PHST- 2014/05/07 00:00 [accepted]
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2014/11/11 06:00 [medline]
AID - S0304-419X(14)00047-X [pii]
AID - 10.1016/j.bbcan.2014.05.002 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2014 Aug;1846(1):161-79. doi: 10.1016/j.bbcan.2014.05.002. 
      Epub 2014 May 13.